- News and analysis
- The Two Most Oversold Medical Cannabis Stocks: Canopy Growth
The Two Most Oversold Medical Cannabis Stocks: Canopy Growth
CGS stock prices are 9% off their peaks. But a looser tax regulation may boost business margins and some investors consider the moment to be appropriate to buy such stocks. According to federal regulations in the United States marijuana or cannabis with more than 0.3% THC is a Schedule 1 drug, the same as heroin, LSD, ecstasy and magic mushrooms. Cocaine and methamphetamine are considered less harmful and are put into the Schedule 2 group. This classification is seriously bounding any promotions of cannabis related products and hampering cannabis producers’ profits. The U.S. Federal law prevents any deduction of related costs, pushing the effective tax rate up to 90%. So, any loosening of taxation and a change of drug classification would greatly benefit cannabis producers.
Tilray reported revenues of Can$122.8 million and a negative gross margin of Can$1.3 million during the last quarter. So, there are no illusions that the majority of cannabis-related business are making a loss. However, potential profits after stocks lose most of their value may be huge even considering existing risks. CGS stocks are traded at $2.4, a price lastly seen in the summer of 2016, before the bubble emerged in this sector. The recovery of stock prices to the levels of early 2022 would mean stock prices up by 300%.
The comments, insights, and reviews posted in this section are solely the opinions and perspectives of authors and do not represent the views or endorsements of RHC Investments or its administrators, except if explicitly indicated. RHC Investments provides a platform for users to share their thoughts on financial market news, investing strategies, and related topics. However, we do not guarantee the accuracy, completeness, or reliability of any user-generated content.
Investment Risks and Advice:
Please be aware that all investment decisions involve risks, and the information shared on metadoro.com should not be considered as financial advice. Always conduct thorough research, seek professional advice, and exercise caution when making investment decisions.
Moderation and Monitoring:
While we strive to maintain a respectful and informative environment, we cannot endorse or verify the accuracy of all user-generated content. We reserve the right to moderate, edit, or remove any comments or posts that violate our community guidelines, infringe on intellectual property rights, or contain harmful content.
By submitting content to metadoro.com, users grant RHC Investments a non-exclusive, royalty-free license to use, display, and distribute the content. Users are responsible for ensuring they have the necessary rights to share the content they post.
To maintain a positive and respectful community, users are expected to adhere to the community guidelines of Metadoro. Any content that is misleading, offensive, or violates applicable laws and regulations will be subject to moderation or removal.
Changes to Disclaimer:
We reserve the right to update, modify, or amend this disclaimer at any time. Users are encouraged to review this disclaimer periodically to stay informed about any changes.